Navigation Links
Common abdominal pain may be due to a potentially treatable newly recognized inflammatory reaction
Date:9/19/2007

JACKSONVILLE, Fla. -- As many as one in four people in westernized countries experience pain or discomfort in their upper abdomen, and physicians have almost nothing to offer except anti-acid medicines, which usually dont work. Now, in a small but novel study, researchers have found evidence that an abnormal amount of inflammatory cells populates the upper intestine of affected individuals, which suggests a fresh way of understanding the common complaint.

The study, published in the September issue of Clinical Gastroenterology and Hepatology and conducted by researchers in the U.S., Sweden, England, and Australia, may also point to innovative methods to treat the condition and eliminate discomfort.

Newly-designed, targeted anti-inflammatory medicine aimed at blocking the function of these cells might be very useful, if our results are validated, says the studys lead researcher, Nicholas J. Talley, M.D., Chair of Internal Medicine at Mayo Clinic in Jacksonville.

We are quite intrigued by what we have discovered, because it probably represents a new disease entity, one that might be capable of diagnosis and management, Dr. Talley says.

The scientists dont know why inflammatory cells are present in one particular region of the small intestine, the duodenum that connects to the stomach, but they theorize that it could result from an allergic reaction to certain foods. Patients examined did not have infections, celiac disease (an autoimmune reaction to gluten protein), or cancer.

I believe food intolerance can lead to motor and sensory abnormalities that are perceived as pain and discomfort, Dr. Talley says. But we have no evidence yet that this is definitely the case.

To conduct the study, researchers in Sweden offered endoscopic examinations to 51 Swedish participants who complained of nonulcer dyspepsia as well as 49 randomly selected participants who had no pain. Dyspepsia is chronic or recurrent pain, or a feeling of abdominal fullness after eating or nausea, and the nonulcer form means there is not any structural abnormality such as an ulcer. For reasons that are not clear, sensitivity to stomach acid occurs in some of these patients, but acid suppression therapy does not work in two-thirds of patients who try it. There are really very few effective therapies, Dr. Talley says.

During the endoscopy procedure, physicians removed biopsy tissue from several places in the small intestine of participants, and the samples were examined by pathologists who did not know who the samples belonged to.

The researchers found significantly more eosinophil cells in people with nonulcer dyspepsia, compared to the control group population, but these cells were found only in the duodenum, the place in the intestine where most chemical digestion takes place. Eosinophils are white blood cells, part of the immune system, which fight parasites.

The researchers cannot yet say whether duodenal esoinophilia is the cause of the pain or an effect of another factor causing the disorder, although Dr. Talley says a casual link remains our hypothesis.

The presence of these cells has been overlooked because no one has used rigorous quantification methods before, and because biopsy examinations of the duodenum are not routinely performed, he says. Now we have a new direction to go in.


'/>"/>

Contact: Kevin Punsky
punsky.kevin@mayo.edu
904-953-0746
Mayo Clinic
Source:Eurekalert

Related medicine news :

1. Developmental, neurologic problems common in extremely preterm infants
2. Iron supplementation for a common side effect
3. Genetic Breakthrough in Common Eye Problem
4. Common Cold Found to Fight Cancer Cells
5. Side Effects Of Some Common Drugs
6. E. coli strains resistant to a common antibiotic
7. Gastrointestinal ills more common in diabetics
8. Toxic effects common with AIDS treatments
9. Common contraception
10. Drooping eyelids more common in men
11. Unnatural death common in mentally ill
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2016)... , ... December 02, 2016 , ... Center for Autism ... caregivers of those affected by autism spectrum disorder (ASD) and other developmental disabilities. The ... Maine, will give parents and other caregivers the opportunity to share stories and advice, ...
(Date:12/2/2016)... ... December 02, 2016 , ... Mediaplanet’s newest campaign, ... standing as living proof that attitude and determination can combine into the most ... spike around the holidays. This campaign will offer patients a new-found hope, by ...
(Date:12/2/2016)... ... December 02, 2016 , ... CloudLIMS.com, a class-leading provider of ... Lite. CloudLIMS Lite helps biobanks, clinical, research and testing laboratories keep track of ... new version is a faster and a more efficient product, allowing batch processing ...
(Date:12/2/2016)... ... ... Rijuven Corp launches rejiva ( http://www.rejiva.com ), a unique wearable technology that measures ... on the market can deliver all that rejiva can. , “Rejiva promotes relaxation and ... than the usual heart rate and steps taken”, adds Evens Augustin, CEO of Rijuven. ...
(Date:12/2/2016)... ... 02, 2016 , ... On November 24th, 2016, Thanksgiving morning, ... different sites throughout Miami-Dade and Broward counties. This is the largest meal delivery ... Thanksgiving morning by putting together individual meals via assembly lines and passing them ...
Breaking Medicine News(10 mins):
(Date:12/2/2016)... 2016 bioLytical Laboratories, un líder mundial en test rápidos ... HIV Self Test , a los miembros de la Kenya Pharmaceutical Association. ... ... INSTI HIV Self Test! (PRNewsFoto/bioLytical Laboratories) ...      (Photo: http://photos.prnewswire.com/prnh/20161201/444905 ) bioLytical fue invitada por la ...
(Date:12/2/2016)... GARDENS, N.Y. , Dec. 2, 2016  LifeVac, ... will be included in the Emergency Response Training and ... are very excited to have LifeVac become part of ... Lih , Founder and CEO of LifeVac. "Having an ... LifeVac safely and effectively will help leverage our efforts ...
(Date:12/2/2016)... 2016 According to a ... by Product (Instruments, Reagents, Software), Technology (Immunoassay, Clinical ... Nephrology, Infectious Diseases) - Forecast to 2021" published ... USD 60.22 Billion in 2016. This market is ... during the forecast period (2016-2021) to reach USD ...
Breaking Medicine Technology: